Andere talen Lucid Diagnostics Inc.

Aandelen

LUCD

US54948X1090

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 11-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,7248 ^USD	-2,70%		-17,13%	-48,60%

13/05	Transcript : Lucid Diagnostics Inc., Q1 2024 Earnings Call, May 13, 2024
13/05	Lucid Diagnostics Inc. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

PAVmed Provides Business Update and First Quarter 2024 Financial Results	14/05
Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Lucid Diagnostics Inc. Announces Legacy Esophageal Cell Collection Device Subject of Class II FDA Recall	09/05
Lucid Diagnostics Inc. Appoints Dennis Matheis as Class A Director	07/05
Lucid Diagnostics Inc. announced that it has received $11.634 million in funding	06/05
Lucid Diagnostics Inc. announced that it expects to receive $11.634 million in funding	01/05
Lucid Diagnostics : Corporate Presentation - March 2024	03/04
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results	27/03
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Lucid Diagnostics Inc. Announces Positive Data from the First Prospective Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population	21/03
Lucid Diagnostics Inc. announced that it has received $18.16 million in funding	13/03
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program	19/02
Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors	09/02
Lucid Diagnostics Inc. Executes Contract to Provide Esoguard® Esophageal Precancer Testing as A Covered Benefit for 9/11 Responders and Survivors	08/02
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies	12/12
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies	12/12
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Lucid Diagnostics Inc. Appoints Shaun M. O?Neil as President	13/11
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023	01/11
Lucid Diagnostics Inc. announced that it has received $5 million in funding	01/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lucid Diagnostics Inc.

Aandelen

LUCD

US54948X1090

Andere talen

Filters